PE20040161A1 - Formulacion farmaceutica que comprende melatonina - Google Patents
Formulacion farmaceutica que comprende melatoninaInfo
- Publication number
- PE20040161A1 PE20040161A1 PE2003000278A PE2003000278A PE20040161A1 PE 20040161 A1 PE20040161 A1 PE 20040161A1 PE 2003000278 A PE2003000278 A PE 2003000278A PE 2003000278 A PE2003000278 A PE 2003000278A PE 20040161 A1 PE20040161 A1 PE 20040161A1
- Authority
- PE
- Peru
- Prior art keywords
- pharmaceutical formulation
- melatonin
- hypnotics
- refers
- annular
- Prior art date
Links
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 title abstract 3
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 title abstract 3
- 229960003987 melatonin Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 239000003326 hypnotic agent Substances 0.000 abstract 2
- 230000000147 hypnotic effect Effects 0.000 abstract 2
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 abstract 1
- 239000004925 Acrylic resin Substances 0.000 abstract 1
- 229920000178 Acrylic resin Polymers 0.000 abstract 1
- 102000004300 GABA-A Receptors Human genes 0.000 abstract 1
- 108090000839 GABA-A Receptors Proteins 0.000 abstract 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen(.) Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 abstract 1
- 229960003991 trazodone Drugs 0.000 abstract 1
- 229960004010 zaleplon Drugs 0.000 abstract 1
- HUNXMJYCHXQEGX-UHFFFAOYSA-N zaleplon Chemical compound CCN(C(C)=O)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C#N)=C1 HUNXMJYCHXQEGX-UHFFFAOYSA-N 0.000 abstract 1
- 229960001475 zolpidem Drugs 0.000 abstract 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 abstract 1
- 229960000820 zopiclone Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL149377A IL149377A (en) | 2002-04-28 | 2002-04-28 | Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20040161A1 true PE20040161A1 (es) | 2004-03-22 |
Family
ID=29227410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003000278A PE20040161A1 (es) | 2002-04-28 | 2003-03-20 | Formulacion farmaceutica que comprende melatonina |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US20050175692A1 (enExample) |
| EP (1) | EP1494650B1 (enExample) |
| JP (1) | JP2005527583A (enExample) |
| KR (1) | KR101000624B1 (enExample) |
| CN (1) | CN100386070C (enExample) |
| AR (1) | AR039232A1 (enExample) |
| AT (1) | ATE507831T1 (enExample) |
| AU (1) | AU2003227304B2 (enExample) |
| BR (1) | BR0308762A (enExample) |
| CA (1) | CA2477516C (enExample) |
| DE (1) | DE60336999D1 (enExample) |
| DK (1) | DK1494650T3 (enExample) |
| EA (1) | EA007954B1 (enExample) |
| ES (1) | ES2366116T3 (enExample) |
| GT (1) | GT200300064A (enExample) |
| HN (1) | HN2003000115A (enExample) |
| IL (1) | IL149377A (enExample) |
| IS (1) | IS2858B (enExample) |
| MX (1) | MXPA04009893A (enExample) |
| NO (1) | NO332525B1 (enExample) |
| NZ (1) | NZ536298A (enExample) |
| PE (1) | PE20040161A1 (enExample) |
| PL (1) | PL209922B1 (enExample) |
| PT (1) | PT1494650E (enExample) |
| TW (1) | TW200305404A (enExample) |
| UA (1) | UA86924C2 (enExample) |
| UY (1) | UY27753A1 (enExample) |
| WO (1) | WO2003086352A1 (enExample) |
| ZA (1) | ZA200407563B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005063297A2 (en) * | 2003-12-24 | 2005-07-14 | Sepracor Inc. | Melatonin combination therapy for improving sleep quality |
| TW200626137A (en) * | 2004-12-13 | 2006-08-01 | Takeda Pharmaceuticals Co | Preventive or therapeutic agent for sleep disorder |
| US20060198872A1 (en) * | 2005-03-07 | 2006-09-07 | Chioma Ikonte | Plant based dietary supplement for improving the duration and quality of sleep |
| KR20070070307A (ko) * | 2005-08-24 | 2007-07-04 | 에스에스 세야쿠 가부시키 가이샤 | 수면 개선 의약 조성물 |
| CN1299680C (zh) * | 2005-08-29 | 2007-02-14 | 陈彦方 | 一种治疗失眠的黑白制剂 |
| AR056076A1 (es) * | 2005-09-20 | 2007-09-19 | Takeda Pharmaceutical | Agente profilactico o terapeutico para el desorden de sueno |
| CN102018681A (zh) * | 2010-12-10 | 2011-04-20 | 荣港生技医药科技（北京）有限公司 | 一种美乐托宁缓释剂、其制备方法及其应用 |
| WO2012103411A2 (en) | 2011-01-28 | 2012-08-02 | Zx Pharma, Llc | Controlled-release melatonin composition and related methods |
| US9532952B2 (en) * | 2011-01-28 | 2017-01-03 | Physician's Seal, LLC | Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients |
| EP2570126B1 (en) * | 2011-09-16 | 2014-03-26 | Darius Rassoulian | Use of melatonin for treating acute alcohol intoxication |
| US10849856B2 (en) | 2016-10-31 | 2020-12-01 | Neurim Pharmaceuticals Ltd. | Melatonin mini-tablets and method of manufacturing the same |
| EP3777842B1 (en) * | 2016-10-31 | 2024-12-11 | Neurim Pharmaceuticals Ltd. | Melatonin mini-tablets and method of manufacturing the same |
| CN109364031A (zh) * | 2018-10-07 | 2019-02-22 | 威海贯标信息科技有限公司 | 一种盐酸曲唑酮片剂组合物 |
| US11723862B2 (en) * | 2020-01-17 | 2023-08-15 | Societe Des Produits Nestle S.A. | Dosage form with sustained release melatonin pellets |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4600723A (en) * | 1983-05-18 | 1986-07-15 | Monash University | Method for minimizing disturbances in circadian rhythms of bodily performance and function |
| US5707652A (en) * | 1990-12-04 | 1998-01-13 | State Of Oregon | Methods of treating circadian rhythm phase disorders |
| IT1251544B (it) * | 1991-05-13 | 1995-05-17 | Gabriele Biella | Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico |
| FR2718020B1 (fr) * | 1994-04-01 | 1996-05-31 | Biotec Centre Sa | Composition galénique mucoadhésive hétérofonctionnelle. |
| AT408188B (de) * | 1995-02-01 | 2001-09-25 | Neurim Pharma 1991 | Verwendung von melatonin zur behandlung von an medikamentensucht leidenden patienten |
| DE69713294T3 (de) * | 1996-03-08 | 2009-01-15 | Takeda Pharmaceutical Co. Ltd. | Tricyclische Verbindungen mit Bindungsaffinität für Melatoninrezeptoren, deren Herstellung und Verwendung |
| AU2583397A (en) * | 1996-04-10 | 1997-10-29 | Chronorx, Llc | Unit dosage forms, containing magnesium, vitamin c, vitamin e, folate and selenium, for treatment of vasoconstriction and related conditions |
| ATE265209T1 (de) * | 1996-07-17 | 2004-05-15 | Merck & Co Inc | Änderung des zirkadischen rhythmus mit nicht- peptidischen neurokinin-1 rezeptor antagonisten |
| DE69910795T2 (de) * | 1998-06-09 | 2004-06-17 | Takeda Chemical Industries, Ltd. | Pharmazeutische kombination mit einer trizyclischen verbindung und mindestens einer von zolpidem, zopiclone und brotizolam, zur behandlung oder verhinderung von schlafstörungen |
| CN1131030C (zh) * | 1999-03-18 | 2003-12-17 | 胡秀云 | 一种由褪黑素和安定制成的调节睡眠的组合物 |
| AU3910700A (en) * | 1999-03-22 | 2000-10-09 | Immugen Pharmaceuticals, Inc. | Treatment of immune diseases |
| IL144900A (en) * | 2001-08-14 | 2013-12-31 | Neurim Pharma 1991 | Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs |
-
2002
- 2002-04-28 IL IL149377A patent/IL149377A/en active IP Right Grant
-
2003
- 2003-03-17 GT GT200300064A patent/GT200300064A/es unknown
- 2003-03-20 BR BR0308762-0A patent/BR0308762A/pt not_active Application Discontinuation
- 2003-03-20 CA CA2477516A patent/CA2477516C/en not_active Expired - Lifetime
- 2003-03-20 PL PL372867A patent/PL209922B1/pl unknown
- 2003-03-20 AU AU2003227304A patent/AU2003227304B2/en not_active Expired
- 2003-03-20 DK DK03746393.2T patent/DK1494650T3/da active
- 2003-03-20 EP EP03746393A patent/EP1494650B1/en not_active Expired - Lifetime
- 2003-03-20 US US10/510,625 patent/US20050175692A1/en not_active Abandoned
- 2003-03-20 ES ES03746393T patent/ES2366116T3/es not_active Expired - Lifetime
- 2003-03-20 JP JP2003583375A patent/JP2005527583A/ja active Pending
- 2003-03-20 UA UA20041008558A patent/UA86924C2/ru unknown
- 2003-03-20 EA EA200401331A patent/EA007954B1/ru not_active IP Right Cessation
- 2003-03-20 CN CNB038075644A patent/CN100386070C/zh not_active Expired - Lifetime
- 2003-03-20 MX MXPA04009893A patent/MXPA04009893A/es active IP Right Grant
- 2003-03-20 NZ NZ536298A patent/NZ536298A/en not_active IP Right Cessation
- 2003-03-20 DE DE60336999T patent/DE60336999D1/de not_active Expired - Lifetime
- 2003-03-20 AT AT03746393T patent/ATE507831T1/de active
- 2003-03-20 PT PT03746393T patent/PT1494650E/pt unknown
- 2003-03-20 WO PCT/IL2003/000240 patent/WO2003086352A1/en not_active Ceased
- 2003-03-20 PE PE2003000278A patent/PE20040161A1/es not_active Application Discontinuation
- 2003-03-20 KR KR1020047015934A patent/KR101000624B1/ko not_active Expired - Lifetime
- 2003-04-01 TW TW092107377A patent/TW200305404A/zh unknown
- 2003-04-02 AR ARP030101156A patent/AR039232A1/es not_active Application Discontinuation
- 2003-04-07 UY UY27753A patent/UY27753A1/es not_active Application Discontinuation
- 2003-04-07 HN HN2003000115A patent/HN2003000115A/es unknown
-
2004
- 2004-08-27 NO NO20043576A patent/NO332525B1/no not_active IP Right Cessation
- 2004-09-21 ZA ZA2004/07563A patent/ZA200407563B/en unknown
- 2004-10-07 IS IS7492A patent/IS2858B/is unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20040161A1 (es) | Formulacion farmaceutica que comprende melatonina | |
| PA8637601A1 (es) | Compuestos moduladores de la actividad de c-kit y usos de los mismos | |
| AR025960A1 (es) | Biblioteca de sustancias que contiene imidazo-5-il-aminas biciclicas y/o imidazo 3-il-aminas biciclicas, procedimiento para la preparacion de estabiblioteca de sustancias, y uso de sustancias de esta biblioteca para la preparacion de medicamentos para el tratamiento del dolor | |
| ECSP18083443A (es) | Formulaciones líquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil) -pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida | |
| EP4105213A4 (en) | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | |
| EE03805B1 (et) | Peroraalselt manustatava farmatseutilise kompositsiooni kasutamine meeste erektiilse talitlushäire raviks ettenähtud ravimi valmistamiseks | |
| UY27595A1 (es) | Compuestos de succinimida heterocíclicos, fusionados y analógos de los mismos, moduladores de la función del receptor de la hormona nuclear | |
| PT1146861E (pt) | Formulacoes de particulas de hidrogel | |
| ATE387430T1 (de) | Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe | |
| DE69830503D1 (de) | Tablette mit verlängerter wirkstoffabgabe zur behandlung der parkinsonkrankheit | |
| BR0112311A (pt) | Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso | |
| PA8594801A1 (es) | Formulaciones farmaceuticas liquidas de palanosetron | |
| HRP20240082T1 (hr) | Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti | |
| CL2004000847A1 (es) | Compuestos derivados de 2-alquinil o 2-alquenil-5amino-pirazolo-[4,3-e]-1,2,4-triazolo[1,5-]pirimidina; composicion farmaceutica, y uso en el tratamiento de enfermedades del sistema nervioso central o un accidente cerebrovascular tal como depresion, | |
| JP2019528302A5 (enExample) | ||
| RU2019132893A (ru) | Комбинированная терапия для лечения рака молочной железы | |
| SI1433478T1 (sl) | Farmacevtske formulacije za tiroidne hormone in postopki za njihovo pripravo | |
| JP2005527583A5 (enExample) | ||
| UY28537A1 (es) | Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos. | |
| WO2005030132A3 (en) | Therapeutic regimens for administering drug combinations | |
| PA8496801A1 (es) | Complejo farmaceutico | |
| TR200601092T1 (tr) | İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar. | |
| HRP20100363T1 (hr) | Nove kombinacije antagonista receptora 5-ht3 s racekatodrilom ili deksekatodrilom | |
| UY27661A1 (es) | Derivados de benzimidazol 1-fenil-2-heteroaril-sustituidos, su uso para preparar medicamentos y preparados farmacéuticos que los contienen. | |
| MX2025007101A (es) | Formulaciones de fármaco de (r)-1-(1-acriloilpiperidin-3-il)-4-amino-3-(4-fenoxifenil)-1h-imidazo[4,5-c]piridin-2(3h)-ona. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |